About the Authors

Gregory J. Kimmel

Contributed equally to this work with: Gregory J. Kimmel, Richard J. Beck

Roles Conceptualization, Data curation, Formal analysis, Methodology, Visualization, Writing – original draft, Writing – review & editing

Affiliation H. Lee Moffitt Cancer Center & Research Institute, Integrated Mathematical Oncology, Tampa, Florida

Richard J. Beck

Contributed equally to this work with: Gregory J. Kimmel, Richard J. Beck

Roles Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing – review & editing

Affiliation H. Lee Moffitt Cancer Center & Research Institute, Integrated Mathematical Oncology, Tampa, Florida

Xiaoqing Yu

Roles Data curation, Resources, Visualization, Writing – review & editing

Affiliation H. Lee Moffitt Cancer Center & Research Institute, Biostatistics & Bioinformatics, Tampa, Florida

Thomas Veith

Roles Data curation, Resources, Visualization

Affiliation H. Lee Moffitt Cancer Center & Research Institute, Integrated Mathematical Oncology, Tampa, Florida

Samuel Bakhoum

Roles Data curation, Resources, Writing – review & editing

Affiliation Memorial Sloan Kettering Cancer Center, Human Oncology & Pathogenesis Program, New York City, New York

Philipp M. Altrock

Roles Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Visualization, Writing – review & editing

Affiliation Max Planck Institute for Evolutionary Biology, Department for Evolutionary Theory, Plön, Germany

Noemi Andor

Roles Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing

noemi.andor@gmail.com

Affiliation H. Lee Moffitt Cancer Center & Research Institute, Integrated Mathematical Oncology, Tampa, Florida

Competing Interests

The authors have declared that no competing interests exist. P.M.A is consulting for CRISPR Therapeutics, Cambridge, MA, and has received research funding (not for this work) from Kite Pharma (a Gilead company). P.M.A’s funding from Kite Pharma does not constitute a conflict of interest for the current study.